Cancer Treatment Ups CV Risk; Therapy’s Next Big Thing; Nude Photos Settlement

Older adults treated for cancer had double the risk of cardiovascular (CV) events, including stroke, as compared with those without cancer, emphasizing the need for long-term monitoring after cancer treatment. (Cancer)

The FDA approved isatuximab (Sarclisa), in combination with bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone, for newly diagnosed, transplant-ineligible multiple myeloma.

Will peptide-drug conjugates become the “next big thing” in targeted cancer therapy? (Endpoints News)

Bristol Myers Squibb and 2seventy bio announced discontinuation of enrollment in the phase III KarMMa-9 trial of idecabtagene vicleucel (Abecma) and lenalidomide in newly diagnosed multiple myeloma with suboptimal response to transplant because of slow patient accrual.

A phase III trial of the fixed-dose combination of the LAG-3 inhibitor favezelimab and pembrolizumab (Keytruda) failed to meet the primary endpoint of overall survival in previously treated, PD-L1-positive, microsatellite stable metastatic colorectal cancer, Merck announced.

Lehigh Valley Health Network in Pennsylvania agreed to pay $65 million to settle a lawsuit after computer hackers posted nude photos of cancer patients online. (CNN)

Adding ruxolitinib (Jakafi) to standard tyrosine kinase therapy for chronic-phase chronic myeloid leukemia significantly increased the frequency of deep molecular response. (SWOG)

AstraZeneca and Daiichi Sankyo announced that the antibody-drug conjugate datopotamab deruxtecan did not meet the prespecified survival endpoint in a phase III trial of inoperable/metastatic hormone receptor-positive, HER2-low or HER2-negative breast cancer previously treated with endocrine therapy.

New HHS rules on research misconduct still do not address the root cause of the problem — the “publish-or-perish” mentality, an opinion piece argues. (STAT)

Black patients with triple-negative breast cancer may be less likely to receive immunotherapy, despite having outcomes similar to those of white patients when they do. (American Association for Cancer Research)